SFG
OVID icon

Sovereign Financial Group’s Ovid Therapeutics OVID Stock Holding History

Sovereign Financial Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80.7K Hold
30,000
– – 0.01% 380
2026
Q1 		$66.6K Buy
30,000
+20,000
+200% +$35.8K 0.01% 358
2025
Q4 		$16.3K Hold
10,000
– – ﹤0.01% 347
2025
Q3 		$13K Buy
+10,000
New +$8.67K ﹤0.01% 326

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Sovereign Financial Group's OVID Position: Q2 2026 in Review

Sovereign Financial Group held its Ovid Therapeutics (OVID) position steady in Q2 2026 at 30,000 shares worth $80.7K. The position accounts for 0.01% of the portfolio, ranked #380.

Sovereign Financial Group first reported a position in OVID in Q3 2025 and has held it in 4 quarters since. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Sovereign Financial Group held 30,000 shares of Ovid Therapeutics worth $80.7K as of Q2 2026.
  • Sovereign Financial Group left its Ovid Therapeutics share count unchanged in Q2 2026.
  • Ovid Therapeutics made up 0.01% of Sovereign Financial Group's portfolio in Q2 2026, its #380 holding.
  • Sovereign Financial Group first reported a position in Ovid Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Sovereign Financial Group's 13F filing for Q2 2026, filed 24 Jul 2026.